2024 Prediction: Tiny Weight-Loss Player to Deliver “Mega” Profits

Here’s how to invest in one of the new year’s most lucrative opportunities... [Derby City Daily logo] [Derby City Daily logo] [2024 Prediction: Tiny Weight-Loss Player to Deliver “Mega” Profits]( By Andy Swan When Novo Nordisk (NVO) launched its Type 2 diabetes treatment, Ozempic (semaglutide), in 2017, it unknowingly triggered a new kind of “gold rush.” The once-weekly injection turned out to be remarkably effective in helping patients lose weight. Novo Nordisk got wise: It quickly spun semaglutide into a weight-loss-approved version, Wegovy. Folks caught on. Demand soared. Within just five years of these revolutionary drugs being on the market, Novo Nordisk’s market value quadrupled – turning it into the single most valuable European company by market cap. [But even that’s nothing compared to what we’re seeing now](. In the first nine months of 2023, Wegovy sales rocketed more than 480%. Eli Lilly’s (LLY) version of the Type 2 diabetes “miracle” drug, Mounjaro (tirzepatide), racked up $1.41 billion in the third quarter alone. [And the profits should only ramp up from here](. Eli Lilly gained FDA approval on Zepbound (tirzepatide), the weight-loss-approved version of Mounjaro, earlier this month. Patients are already clamoring to get their hands on it. And pill versions of these weight-loss drugs are on the way from both NVO and LLY to make these medications more accessible than ever. Getting in Early on the Weight-Loss “Mega” Trend Industry watchers believe this could be the most lucrative drug class to ever hit the market. Projections put semaglutide’s eventual annual value [as high as $300 billion](. And again, that’s just for Novo Nordisk’s semaglutide. It makes sense: Obesity is a big problem, affecting 42% of adults in America, according to the National Institutes of Health (NIH). A “magic pill” is a whole lot more alluring than diet and exercise. And influential celebrities from NBA great Charles Barkley to [Tesla (TSLA) CEO Elon Musk]( touting their success stories have only added fuel to the fire. With a direct line to what’s hot on Main Street, we’ve been keeping close tabs on this weight-loss “mega” trend here at LikeFolio. We could see consumers talking about taking these weight-loss drugs at unprecedented levels... That early lead allowed our followers to bank 174% on WW International (WW) earlier this year. The company (formerly known as WeightWatchers) acquired telehealth provider Sequence, giving it the ability to connect its users via medical doctors to those trendy weight-loss drugs. It was enough to send WW shares flying more than 50% in a single day. And we can show you the next big weight-loss winner today... Spotting the Next Big Weight-Loss Winner [With this opportunity]( we’re not chasing after those half-a-trillion-dollar pharmaceutical giants. We’re tapping into our LikeFolio edge – identifying the [under-the-radar player]( gaining momentum on Main Street and placing our trade well before the Wall Street pros. LikeFolio data points to a 68% year-over-year increase in consumer demand for [this tiny telehealth company]( that’s set to enter the lucrative weight-loss race by year-end. Most investors haven’t even caught on to that fact, which is why shares are still trading under $10. But once January rolls around, and its weight-loss business launches, [this name]( will be on every investor’s lips. You’ll want to at least [be armed with the details]( before that happens. [Landon and I will give you the inside scoop on our biggest prediction of 2024 right here](. [Click here to access now]( Until next time, [Andy Swan's signature] [Andy Swan's signature] Andy Swan Founder, LikeFolio Get Instant Access Click to read these free reports and automatically sign up for research throughout the week. [25 Doomed Blue Chip Stocks]( [How A.I. Investing Can Improve Your Portfolio]( © 2023 TradeSmith, LLC t/a Derby City Insights. All Rights Reserved. 1125 N. Charles Street, Baltimore, MD 21201 To unsubscribe or change your email preferences, please [click here](. [Terms of Use]( | [Privacy Policy](